ESM1 and cancer: The major finding of the present work was the demonstration that, in the first week after cancer cell inoculation, glycocalyx disruption (SDC-1 and ESM-1), endothelial inflammation (sVCAM-1) and increased vascular permeability (Angpt-2) were present, as evidenced by elevated plasma concentrations of respective biomarkers.